Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 189
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
J Pediatr Hematol Oncol ; 46(1): e107-e110, 2024 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-37916829

RESUMEN

Methotrexate is a major component of pediatric leukemia treatment. While toxicities are common after high-dose methotrexate, escalating dose methotrexate (Capizzi methotrexate) is typically well-tolerated. We report an adolescent Hispanic female with pre-B acute lymphoblastic leukemia, preexisting obesity and hepatic steatosis who developed severe multiorgan failure following an escalating dose of methotrexate with delayed methotrexate excretion of 11 days. We identified one similar report in an obese adult; however, this case is the first to our knowledge involving a pediatric patient. With the rising incidence of obesity and associated comorbidities among children and adolescents with leukemia, attention to potential risks for this population is warranted.


Asunto(s)
Obesidad Infantil , Leucemia-Linfoma Linfoblástico de Células Precursoras B , Leucemia-Linfoma Linfoblástico de Células Precursoras , Adulto , Niño , Humanos , Adolescente , Femenino , Metotrexato/efectos adversos , Obesidad Infantil/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/complicaciones , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
2.
Pediatr Hematol Oncol ; 41(2): 135-149, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-37865916

RESUMEN

High-dose methotrexate (HDMTX) is used to treat a broad spectrum of cancers. Methotrexate (MTX) monitoring and adequate supportive care are critical for safe drug administration; however, MTX level timing is not always possible in low- and middle-income countries. The aim of this study was to evaluate HDMTX supportive care capacity and MTX monitoring practices in Latin America (LATAM) to identify gaps and opportunities for improvement. A multicenter survey was conducted among LATAM pediatric oncologists. Twenty healthcare providers from 20 institutions answered the online questionnaire. HDMTX was used to treat acute lymphoblastic leukemia (ALL; 100%), non-Hodgkin lymphoma (84.2%), diffuse large B-cell lymphoma (47.4%), osteosarcoma (78.9%), and medulloblastoma (31.6%). Delays in starting HDMTX infusion were related to bed shortages (47.4%) and MTX shortages (21.1%). MTX monitoring was performed at an in-hospital laboratory in 52%, at an external/nearby laboratory in 31.6%, and was not available in 10.5%. Median interval between sampling and obtaining MTX levels was ≤ 2 h in 45% and ≥ 6 h in 30%, related to laboratory location. Sites without access to MTX monitoring reduced the MTX dose for patients with high-risk ALL or did not include MTX in the treatment of patients with osteosarcoma. Respondents reported that implementation of point-of-care testing of MTX levels is feasible. In LATAM, highly variable supportive care capacity may affect the safe administration of MTX doses. Improving accessibility of MTX monitoring and the speed of obtaining results should be prioritized to allow delivery of full doses of MTX required by the current protocols.


Asunto(s)
Neoplasias Óseas , Neoplasias Cerebelosas , Osteosarcoma , Niño , Humanos , Metotrexato/uso terapéutico , Antimetabolitos Antineoplásicos/efectos adversos , América Latina/epidemiología , Osteosarcoma/tratamiento farmacológico , Neoplasias Óseas/tratamiento farmacológico
3.
Cancer ; 129(5): 771-779, 2023 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-36504077

RESUMEN

BACKGROUND: Children with relapsed acute lymphoblastic leukemia (ALL) in low-income and middle-income countries rarely survive. The Pediatric Hematology-Oncology Association of Central America (AHOPCA) developed the AHOPCA-ALL REC 2014 protocol to improve outcomes in resource-constrained settings without access to stem cell transplantation. METHODS: The AHOPCA-ALL REC 2014 protocol was based on a modified frontline induction phase 1A, a consolidation therapy with six modified R-blocks derived from the ALL-Berlin-Frankfurt-Munster REZ 2002 protocol and intermittent maintenance therapy. Children with B-lineage ALL were eligible after a late medullary relapse, an early or late combined relapse, or any extramedullary relapses. Those with T-lineage ALL were eligible after early and late extramedullary relapses, as were those with both B-lineage and T-lineage relapses occurring at least 3 months after therapy abandonment. RESULTS: The study population included 190 patients with T-lineage (n = 3) and B-lineage (n = 187) ALL. Of those with B-lineage ALL, 25 patients had a very early extramedullary relapse, 40 had an early relapse (32 extramedullary and 8 combined), and 125 had a late relapse (34 extramedullary, 19 combined, and 72 medullary). The main cause of treatment failure was second relapse (52.1%). The 3-year event-free survival rate (± standard error) was 25.9% ± 3.5%, and the 3-year overall survival rate was 36.7% ± 3.8%. The 3-year event-free survival rate was 47.2% ± 4.7% for late relapses. The most frequently reported toxicity was grade 3 or 4 infection. Mortality during treatment occurred in 17 patients (8.9%), in most cases because of infectious complications. CONCLUSIONS: Selected children with relapsed ALL in Central America can be cured with second-line regimens even without access to consolidation with stem cell transplantation. Children in low-income and middle-income countries who have lower risk relapses of ALL should be treated with curative intent.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Leucemia-Linfoma Linfoblástico de Células Precursoras , Niño , Humanos , Países en Desarrollo , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Recurrencia , Protocolos de Quimioterapia Combinada Antineoplásica , Pobreza
4.
Br J Clin Pharmacol ; 89(2): 660-671, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-35998099

RESUMEN

AIMS: High-dose methotrexate (HDMTX) is an essential part of the treatment of several adult and paediatric malignancies. Despite meticulous supportive care during HDMTX administration, severe toxicities, including acute kidney injury (AKI), may occur contributing to patient morbidity. Population pharmacokinetics provide a powerful tool to predict time to clear HDMTX and adjust subsequent doses. We sought to develop and validate pharmacokinetic models for HDMTX in adults with diverse malignancies and to relate systemic exposure with the occurrence of severe toxicity. METHODS: Anonymized, de-identified data were provided from 101 US oncology practices that participate in the Guardian Research Network, a non-profit clinical research consortium. Modelled variables included clinical, laboratory, demographic and pharmacological data. Population pharmacokinetic analysis was performed by means of nonlinear mixed effects modelling using MonolixSuite. RESULTS: A total of 693 HDMTX courses from 243 adults were analysed, of which 62 courses (8.8%) were associated with stage 2/3 acute kidney injury (43 stage 2, 19 stage 3). A three-compartment model adequately fitted the data. Time-dependent serum creatinine, baseline serum albumin and allometrically scaled bodyweight were clinically significant covariates related to methotrexate clearance. External evaluation confirmed a satisfactory predictive performance of the model in adults receiving HDMTX. Dose-normalized methotrexate concentration at 24 and 48 hours correlated with AKI incidence. CONCLUSION: We developed a population pharmacometric model that considers weight, albumin and time-dependent creatinine that can be used to guide supportive care in adult patients with delayed HDMTX elimination.


Asunto(s)
Lesión Renal Aguda , Neoplasias , Niño , Humanos , Adulto , Metotrexato , Antimetabolitos Antineoplásicos , Neoplasias/tratamiento farmacológico , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/epidemiología , Convulsiones/tratamiento farmacológico
5.
Pediatr Blood Cancer ; 69(4): e29568, 2022 04.
Artículo en Inglés | MEDLINE | ID: mdl-35084087

RESUMEN

BACKGROUND: Tumor boards are part of standard care of patients with complex cancers, but appropriate multidisciplinary expertise and infrastructure are often not available in low- and middle-income countries (LMIC) for pediatric cancers, such as neuroblastoma. Our goal was to review results of a Global Neuroblastoma Network (GNN) tumor board accessible to LMIC. METHODS: De-identified clinical cases presented via internet conference during a weekly GNN virtual tumor board from 2010 through 2020 were evaluated in a standardized format, including diagnostic imaging, pathology, therapy information, resource limitations, and questions for discussion. Information summarized included the presentations, a survey of the impact on care, and a resource questionnaire. RESULTS: Registered GNN participants included 575 individuals from 77 countries, with a median of 39 participants per session. Total 412 cases were presented from 32 countries, including 351 unique neuroblastoma patients, 52 follow-up cases, and nine non-neuroblastoma diagnoses. Twenty-eight educational sessions were presented. Limited critical resources for diagnostics and staging of cases included MYCN analysis (54.7%), metaiodobenzylguanidine (MIBG) scans (38.7%), and International Neuroblastoma Pathology Classification (49%). Therapies were also limited, with markedly decreased use of radiation and autologous stem cell transplant for high-risk cases, and no availability of anti-GD2 antibody in LMIC. Limited sampling with a post-presentation survey showed that 100% found the GNN helpful, and 70% altered the care plan based on the discussion. CONCLUSION: This report shows the utility of an international tumor board for LMIC focused on a challenging solid tumor where local expertise may be limited, with international multidisciplinary expert participation and educational sessions.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas , Neuroblastoma , 3-Yodobencilguanidina , Niño , Humanos , Neuroblastoma/patología , Cintigrafía , Trasplante Autólogo
6.
Pediatr Blood Cancer ; 68(11): e29315, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34455693

RESUMEN

In November 2018, theInternational Society of Paediatric Oncology (SIOP) launched a project to map African facilities providing pediatric oncology treatment. A 55-item digital survey was created in English, piloted in India, translated to French and Portuguese, and distributed by email, social media, or personal contacts. December 2019, 48/54 African countries responded (72% surveys completed and analyzed). Issues included incomplete responses, multiple entries for one facility with conflicting data for key services, and repeated entries with varied answers by the same respondent. The facility mapping project, now on-going program will serve as a global registry of global pediatric cancer centers.


Asunto(s)
Oncología Médica , Neoplasias , Pediatría , África , Niño , Humanos , Oncología Médica/tendencias , Neoplasias/epidemiología , Neoplasias/terapia , Pediatría/tendencias , Sistema de Registros , Sociedades Médicas , Encuestas y Cuestionarios
7.
Pediatr Blood Cancer ; 68(11): e29345, 2021 11.
Artículo en Inglés | MEDLINE | ID: mdl-34519435

RESUMEN

INTRODUCTION: Inalignment with the World Health Organization (WHO) Global Initiative for Childhood Cancer (GICC), the International Society of Pediatric Oncology initiated a program to map global pediatric oncology services. As survival rates in Africa are low and data are scant, this continent was mapped first to identify areas with greatest need. METHODS: Beginning November 2018, an electronic survey was sent to all known stakeholders, followed by email communications and internet searches to verify data. Availability of pediatric oncologists, chemotherapy, surgical expertise, and radiotherapy was correlated with geographic region, World Bank income status, Universal Health Coverage, population < 15 and < 24 years, percentage of gross domestic product spent on healthcare, and Human Development Index (HDI). RESULTS: Responses were received from 48/54 African countries. All three treatment modalities were reportedly available in 9/48 countries, whereas seven countries reported no pediatric oncology services. Negative correlations were detected between provision of all three services and geographic region (P = 0.01), younger median population age (P = 0.002), low-income country status (P = 0.045), and lower HDI (P < 0.001). CONCLUSION: This study provides a comprehensive overview of pediatric oncology care in Africa, emphasizing marked disparities between countries: some have highly specialized services, whereas others have no services. A long-term strategy to eliminate disparities in African pediatric cancer care should be aligned with the WHO GICC aims and facilitated by SIOP Africa. MEETING ABSTRACTS: SIOP maps pediatric oncology services in Africa to address inequalities in childhood cancer services. Geel J, Ranasinghe N, Davidson A, Challinor J, Howard S, Wollaert S, Myezo K, Renner L, Hessissen L, Bouffet E. 51st Annual Congress of the International Society of Paediatric Oncology (SIOP), Lyon, France, October 2019. Pediatric Blood and Cancer Vol 66 S219-S219. Pediatric cancer care in Africa: SIOP Global Mapping Program report on economic and population indicators.


Asunto(s)
Oncología Médica , Neoplasias , Pediatría , África , Niño , Humanos , Oncología Médica/tendencias , Neoplasias/epidemiología , Neoplasias/terapia , Pediatría/tendencias , Factores Socioeconómicos , Encuestas y Cuestionarios , Tasa de Supervivencia
8.
Eur J Clin Pharmacol ; 77(8): 1123-1131, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-33624119

RESUMEN

PURPOSE: Computerised prescriber (or physician) order entry (CPOE) implementation is one of the strategies to reduce medication errors. The extent to which CPOE influences the incidence of chemotherapy-related medication errors (CMEs) was not previously collated and systematically reviewed. Hence, this study was designed to collect, collate, and systematically review studies to evaluate the effect of CPOE on the incidence of CMEs. METHODS: A search was performed of four databases from 1 January 1995 until 1 August 2019. English-language studies evaluating the effect of CPOE on CMEs were selected as per inclusion and exclusion criteria. The total CMEs normalised to total prescriptions pre- and post-CPOE were extracted and collated to perform a meta-analysis using the 'meta' package in R. The systematic review was registered with PROSPERO CRD42018104220. RESULTS: The database search identified 1621 studies. After screening, 19 studies were selected for full-text review, of which 11 studies fulfilled the selection criteria. The meta-analysis of eight studies with a random effects model showed a risk ratio of 0.19 (95% confidence interval: 0.08-0.44) favouring CPOE (I2 = 99%). CONCLUSION: The studies have shown consistent reduction in CMEs after CPOE implementation, except one study that showed an increase in CMEs. The random effects model in the meta-analysis of eight studies showed that CPOE implementation reduced CMEs by 81%.


Asunto(s)
Antineoplásicos/administración & dosificación , Sistemas de Entrada de Órdenes Médicas/estadística & datos numéricos , Errores de Medicación/prevención & control , Comportamiento del Consumidor , Humanos , Gravedad del Paciente
9.
Cancer ; 126(21): 4697-4705, 2020 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-32780447

RESUMEN

BACKGROUND: Cervical cancer is a preventable cancer; therefore, countries should provide strategic, evidence-based health services to reduce its incidence and impact on their populations. Two packages of health services that group together all the services related to cervical cancer, the Essential Cancer Package (9 interventions) and the Primary Care Package (5 interventions), are defined in this article with the aim of assessing the global status of the availability of health services and their coverage in 194 countries worldwide. METHODS: The study was based on the 2017 World Health Organization (WHO) Noncommunicable Disease Country Capacity Survey. Although the survey covered multiple noncommunicable diseases, this report examined only those results pertaining to cervical cancer in the 194 WHO member states divided by WHO region and World Bank income. RESULTS: Only 21% of the countries reported providing all 9 interventions of the Essential Cancer Package, with the highest proportions being found in Europe (45.3%) and among high-income countries (HICs; 54.3%). As for the Primary Care Package, only 19.1% of countries provided all 5 interventions, with the highest proportions being found in Europe (39.6%) and among HICs (45.5%). CONCLUSIONS: The complete development and appropriate coverage of each service listed in both the Essential Cancer Package and the Primary Care Package are essential to reduce the impact of cervical cancer worldwide, and they should be integrated into all cancer control planning efforts.


Asunto(s)
Atención a la Salud/métodos , Atención Primaria de Salud/métodos , Neoplasias del Cuello Uterino/epidemiología , Femenino , Humanos
10.
Br J Haematol ; 185(6): 1125-1135, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30740656

RESUMEN

In high-income countries, more than 90% of children with mature B-cell lymphomas are cured with frontline therapy. However, cure requires prompt and correct diagnosis, careful risk stratification, very intense chemotherapy and meticulous supportive care, together with logistical support for patients who live far from the cancer centre or face financial barriers to receiving care. In low- and middle-income countries (LMIC), cure rates range from 20% to 70% because of lack of diagnosis, misdiagnosis, abandonment of treatment, toxic death and excess relapse with reduced-intensity regimens. Fortunately, a wide range of successful interventions in LMIC have reduced these causes of avoidable treatment failure. Public awareness campaigns have led to societal awareness of childhood cancer; telepathology has improved diagnosis, even in remote areas; subsidized chemotherapy, transportation, housing and food have reduced abandonment; and hand hygiene, nurse training programmes and health system improvements have reduced toxic death. These interventions can be deployed everywhere and at low cost, so are highly scalable. Children and adolescents with Burkitt lymphoma can be cured in all countries by making a timely correct diagnosis, applying protocols adapted to the local context, preventing abandonment of therapy and avoiding toxic death. Reducing these causes of treatment failure is feasible and highly cost-effective everywhere.


Asunto(s)
Linfoma no Hodgkin/epidemiología , Niño , Preescolar , Terapia Combinada , Países en Desarrollo , Manejo de la Enfermedad , Detección Precoz del Cáncer , Salud Global , Humanos , Renta , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/terapia , Evaluación del Resultado de la Atención al Paciente , Vigilancia de la Población , Pobreza , Negativa al Tratamiento
11.
Lancet Oncol ; 19(5): e252-e266, 2018 05.
Artículo en Inglés | MEDLINE | ID: mdl-29726390

RESUMEN

In low-income and middle-income countries, an excess in treatment failure for children with cancer usually results from misdiagnosis, inadequate access to treatment, death from toxicity, treatment abandonment, and relapse. The My Child Matters programme of the Sanofi Espoir Foundation has funded 55 paediatric cancer projects in low-income and middle-income countries over 10 years. We assessed the impact of the projects in these regions by using baseline assessments that were done in 2006. Based on these data, estimated 5-year survival in 2016 increased by a median of 5·1%, ranging from -1·5% in Venezuela to 17·5% in Ukraine. Of the 26 861 children per year who develop cancer in the ten index countries with My Child Matters projects that were evaluated in 2006, an estimated additional 1343 children can now expect an increase in survival outcome. For example, in Paraguay, a network of paediatric oncology satellite clinics was established and scaled up to a national level and has managed 884 patients since initiation in 2006. Additionally, the African Retinoblastoma Network was scaled up from a demonstration project in Mali to a network of retinoblastoma referral centres in five sub-Saharan African countries, and the African School of Paediatric Oncology has trained 42 physicians and 100 nurses from 16 countries. The My Child Matters programme has catalysed improvements in cancer care and has complemented the efforts of government, civil society, and the private sector to sustain and scale improvements in health care to a national level. Key elements of successful interventions include strong and sustained local leadership, community engagement, international engagement, and capacity building and support from government.


Asunto(s)
Prestación Integrada de Atención de Salud/métodos , Países en Desarrollo , Disparidades en Atención de Salud , Oncología Médica/métodos , Neoplasias/terapia , Pediatría/métodos , Asociación entre el Sector Público-Privado , Adolescente , Edad de Inicio , Niño , Preescolar , Prestación Integrada de Atención de Salud/economía , Países en Desarrollo/economía , Disparidades en Atención de Salud/economía , Humanos , Renta , Lactante , Recién Nacido , Oncología Médica/economía , Neoplasias/diagnóstico , Neoplasias/economía , Neoplasias/mortalidad , Pediatría/economía , Pronóstico , Desarrollo de Programa , Evaluación de Programas y Proyectos de Salud , Asociación entre el Sector Público-Privado/economía , Medición de Riesgo , Factores de Riesgo
12.
Annu Rev Pharmacol Toxicol ; 55: 89-106, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25292429

RESUMEN

Although the field of pharmacogenetics has existed for decades, practioners have been slow to implement pharmacogenetic testing in clinical care. Numerous publications describe the barriers to clinical implementation of pharmacogenetics. Recently, several freely available resources have been developed to help address these barriers. In this review, we discuss current programs that use preemptive genotyping to optimize the pharmacotherapy of patients. Array-based preemptive testing includes a large number of relevant pharmacogenes that impact multiple high-risk drugs. Using a preemptive approach allows genotyping results to be available prior to any prescribing decision so that genomic variation may be considered as an inherent patient characteristic in the planning of therapy. This review describes the common elements among programs that have implemented preemptive genotyping and highlights key processes for implementation, including clinical decision support.


Asunto(s)
Centros Médicos Académicos/organización & administración , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/genética , Farmacogenética/organización & administración , Servicio de Farmacia en Hospital/organización & administración , Medicina de Precisión , Técnicas de Apoyo para la Decisión , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Educación Médica , Pruebas Genéticas , Genotipo , Humanos , Modelos Organizacionales , Seguridad del Paciente , Selección de Paciente , Farmacogenética/educación , Fenotipo , Valor Predictivo de las Pruebas , Desarrollo de Programa , Evaluación de Programas y Proyectos de Salud , Medición de Riesgo , Factores de Riesgo , Estados Unidos
13.
Lancet ; 387(10033): 2133-2144, 2016 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-26578033

RESUMEN

Investments in cancer control--prevention, detection, diagnosis, surgery, other treatment, and palliative care--are increasingly needed in low-income and particularly in middle-income countries, where most of the world's cancer deaths occur without treatment or palliation. To help countries expand locally appropriate services, Cancer (the third volume of nine in Disease Control Priorities, 3rd edition) developed an essential package of potentially cost-effective measures for countries to consider and adapt. Interventions included in the package are: prevention of tobacco-related cancer and virus-related liver and cervical cancers; diagnosis and treatment of early breast cancer, cervical cancer, and selected childhood cancers; and widespread availability of palliative care, including opioids. These interventions would cost an additional US$20 billion per year worldwide, constituting 3% of total public spending on health in low-income and middle-income countries. With implementation of an appropriately tailored package, most countries could substantially reduce suffering and premature death from cancer before 2030, with even greater improvements in later decades.


Asunto(s)
Atención a la Salud/economía , Salud Global/economía , Neoplasias/economía , Países en Desarrollo/estadística & datos numéricos , Salud Global/estadística & datos numéricos , Humanos , Renta , Neoplasias/diagnóstico , Neoplasias/mortalidad , Neoplasias/terapia
14.
BMC Cancer ; 17(1): 280, 2017 04 18.
Artículo en Inglés | MEDLINE | ID: mdl-28420351

RESUMEN

BACKGROUND: Tumor epithelial cells (TEpCs) and spindle-shaped stromal cells, not associated with the vasculature, of patients with early breast cancer express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), receptor activator of nuclear factor kappa B ligand, stromal cell derived factor-1, interleukin-6, macrophage colony stimulating factor, chemokine (C-C motif) ligand-2 (CCL-2) and their receptors at significantly higher levels compared with non-neoplastic breast tissues. We evaluated the clinicopathological significance of these ligands and receptors in TEpC and spindle-shaped stromal cells, not associated with the vasculature, to determine their impact on prognosis of patients with early-stage breast cancer. METHODS: We conducted immunohistochemical analyses of protein expression in primary tumors of patients with early breast cancer and analyzed their association with standard prognostic parameters and clinical outcomes, including local relapse, metastatic recurrence, disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS). RESULTS: Elevated levels of TRAIL-R3 and chemokine (C-C motif) receptor 2 (CCR-2) in TEpCs and OPG and CCL-2 in stromal cells were significantly associated with a higher risk of metastasis (p = 0.032, p = 0.003, p = 0.038, and p = 0.049; respectively). Moreover, high expression of TRAIL-R3 and CCR-2 in TEpCs was associated with shorter DFS, MFS, and OS. High TRAIL-R3 expression in TEpCs was an independent prognostic factor for DFS and OS, and high CCR-2 expression in these cells was an independent prognostic factor for MFS. CONCLUSIONS: High levels of TRAIL-R3 and CCR-2 expression in TEpCs identified patients with early breast cancer with poor outcomes.


Asunto(s)
Biomarcadores de Tumor/análisis , Neoplasias de la Mama/patología , Células Epiteliales/metabolismo , Receptores CCR2/biosíntesis , Miembro 10c de Receptores del Factor de Necrosis Tumoral/biosíntesis , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/mortalidad , Células Epiteliales/patología , Femenino , Proteínas Ligadas a GPI/análisis , Proteínas Ligadas a GPI/biosíntesis , Humanos , Inmunohistoquímica , Persona de Mediana Edad , Pronóstico , Receptores CCR2/análisis , Miembro 10c de Receptores del Factor de Necrosis Tumoral/análisis , Estudios Retrospectivos
15.
Pediatr Blood Cancer ; 64(10)2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28423236

RESUMEN

BACKGROUND: Treatment refusal and abandonment are major causes of treatment failure for children with cancer in low- and middle-income countries (LMICs), like Guatemala. This study identified risk factors for and described the intervention that decreased abandonment. METHODS: This was a retrospective study of Guatemalan children (0-18 years) with cancer treated at the Unidad Nacional de Oncología Pediátrica (UNOP), 2001-2008, using the Pediatric Oncology Network Database. Treatment refusal was a failure to begin treatment and treatment abandonment was a lapse of 4 weeks or longer in treatment. The impact of medicina integral, a multidisciplinary psychosocial intervention team at UNOP was evaluated. Cox proportional hazards analysis identified the effect of demographic and clinical factors on abandonment. Kaplan-Meier analysis estimated the survival. RESULTS: Of 1,789 patients, 21% refused or abandoned treatment. Abandonment decreased from 27% in 2001 to 7% in 2008 following the implementation of medicina integral. Factors associated with increased risk of refusal and abandonment: greater distance to the centre (P < 0.001), younger age (P = 0.017) and earlier year of diagnosis (P < 0.001). Indigenous race/ethnicity (P = 0.002) was associated with increased risk of abandonment alone. Abandonment correlated with decreased overall survival: 0.57 ± 0.02 (survival ± standard error) for those who completed therapy versus 0.06 ± 0.02 for those who abandoned treatment (P < 0.001) at 8.3 years. CONCLUSION: This study identified distance, age, year of diagnosis and indigenous race/ethnicity as risk factors for abandonment. A multidisciplinary intervention reduced abandonment and can be replicated in other LMICs.


Asunto(s)
Neoplasias/mortalidad , Neoplasias/terapia , Negativa al Tratamiento , Adolescente , Cuidados Posteriores , Niño , Preescolar , Supervivencia sin Enfermedad , Femenino , Guatemala/epidemiología , Humanos , Lactante , Masculino , Estudios Retrospectivos , Tasa de Supervivencia
16.
Pediatr Blood Cancer ; 64 Suppl 52017 12.
Artículo en Inglés | MEDLINE | ID: mdl-29297617

RESUMEN

Pediatric radiotherapy is a critical part of pediatric oncology protocols and the quality of the radiotherapy may determine the future quality of life for long-term survivors. Multidisciplinary team decision making provides the basis for high-quality care. However, delivery of high-quality radiotherapy is dependent on resources. This article provides guidelines for delivery of good quality radiation therapy in resource-limited countries based on rational procurement and maintenance planning, protocol development, three-dimensional planning, quality assurance, and adequate staff numbers and training.


Asunto(s)
Países en Desarrollo , Neoplasias/radioterapia , Oncología por Radiación , Radioterapia/métodos , Niño , Humanos , Oncología por Radiación/métodos , Oncología por Radiación/normas , Sociedades Médicas
17.
Pediatr Blood Cancer ; 64 Suppl 52017 12.
Artículo en Inglés | MEDLINE | ID: mdl-29297619

RESUMEN

Many children with cancer in low- and middle-income countries are treated in hospitals lacking key infrastructure, including diagnostic capabilities, imaging modalities, treatment components, supportive care, and personnel. Childhood cancer treatment regimens adapted to local conditions provide an opportunity to cure as many children as possible with the available resources, while working to improve services and supportive care. This paper from the Adapted Treatment Regimens Working Group of the Pediatric Oncology in Developing Countries committee of the International Society of Pediatric Oncology outlines the design, development, implementation, and evaluation of adapted regimens and specifies levels of services needed to deliver them.


Asunto(s)
Países en Desarrollo , Necesidades y Demandas de Servicios de Salud , Oncología Médica , Neoplasias/tratamiento farmacológico , Niño , Humanos , Oncología Médica/métodos , Oncología Médica/normas , Sociedades Médicas
18.
Pediatr Blood Cancer ; 64(7)2017 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-28097818

RESUMEN

International harmonization of staging evaluation and response criteria is needed for childhood, adolescence, and young adulthood Hodgkin lymphoma. Two Hodgkin lymphoma protocols from cooperative trials in Europe and North America were compared for areas in need of harmonization, and an evidence-based approach is currently underway to harmonize staging and response evaluations with a goal to enhance comparisons, expedite identification of effective therapies, and aid in the approval process for new agents by regulatory agencies.


Asunto(s)
Enfermedad de Hodgkin/patología , Estadificación de Neoplasias/métodos , Estadificación de Neoplasias/normas , Adolescente , Niño , Femenino , Humanos , Masculino , Adulto Joven
19.
J Pediatr Hematol Oncol ; 39(2): e79-e81, 2017 03.
Artículo en Inglés | MEDLINE | ID: mdl-27467369

RESUMEN

A 2-year-old boy presented with pneumonia and an abdominal mass was noted incidentally. A right lobe hepatic mass classified as PRETEXT III and congenital absence of the portal vein with drainage of the superior mesenteric vein to the inferior vena cava (Abernethy malformation type I) were confirmed by computed tomography and angiography. After a clinical diagnosis of hepatoblastoma had been made, he was treated with 4 cycles of doxorubicin and cisplatin and hepatic arterial chemoembolization with doxorubicin, after which the tumor was classified as POSTEXT III. He underwent a right extended hepatic lobectomy with resection of the caudate lobe but died on postoperative day 4 due to hepatic failure. The Abernethy malformation type I is associated with the development of hepatic tumors, and the abnormal blood flow might predispose to hepatic failure after liver resection. Extensive study of the hepatic vasculature is warranted in patients with suspected malformations. Liver transplant could be considered in patients with congenital portosystemic shunt and malignant liver tumors.


Asunto(s)
Hepatoblastoma/etiología , Neoplasias Hepáticas/etiología , Venas Mesentéricas/anomalías , Vena Porta/anomalías , Malformaciones Vasculares/complicaciones , Vena Cava Inferior/anomalías , Angiografía , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioembolización Terapéutica , Preescolar , Cisplatino/administración & dosificación , Doxorrubicina/administración & dosificación , Resultado Fatal , Hepatectomía/métodos , Hepatoblastoma/diagnóstico por imagen , Hepatoblastoma/tratamiento farmacológico , Hepatoblastoma/cirugía , Humanos , Fallo Hepático/etiología , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/cirugía , Masculino , Venas Mesentéricas/diagnóstico por imagen , Vena Porta/diagnóstico por imagen , Complicaciones Posoperatorias/etiología , Choque Hemorrágico/etiología , Tomografía Computarizada por Rayos X , Malformaciones Vasculares/diagnóstico por imagen , Malformaciones Vasculares/terapia , Vena Cava Inferior/diagnóstico por imagen
20.
J Pediatr Hematol Oncol ; 39(5): 362-364, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28486261

RESUMEN

This study represents findings from a questionnaire completed before a cancer control workshop by 47 pediatric cancer control stakeholder participants from 27 countries. Respondents reported their knowledge of their country's cancer control plan, their understanding of childhood cancer control priorities in their local setting, and barriers to high-quality pediatric cancer care. Findings reveal a knowledge gap in pediatric oncology professionals' awareness of national cancer control plan existence, with under-recognition of existing plans, and uncertainty regarding whether pediatric cancer was included in the plans. This study supports the potential of a preworkshop needs assessment to inform cancer control planning objectives and a cancer control training agenda.


Asunto(s)
Educación , Neoplasias/prevención & control , Niño , Atención a la Salud , Conocimientos, Actitudes y Práctica en Salud , Humanos , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA